Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Oyeyemi Akala
Observed names:
Dr Oyeyemi Akala,
O. Akala
Institutions:
Institute of Cancer Research,
University of Leicester,
University Hospitals of Leicester NHS Trust
Observed institutions:
Nottingham University Hospitals NHS Trust,
Institute of Cancer Research,
University of Leicester,
Leicester Royal Infirmary,
University Hospitals of Leicester NHS Trust
ORCID:
0009-0007-2585-2807
Observed ORCID:
0009-0007-2585-2807
OpenAlex ID:
A5011100739
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma
2024
·
Richard Culliford
, Samuel E. D. Lawrence
, et al.
·
Nature Communications
·
26
PDF
Bilateral optic neuritis attributed to Pembrolizumab: A case report
2024
·
Dr Lucy G Faulkner
, Dr Oyeyemi Akala
, et al.
·
Current Problems in Cancer Case Reports
·
3
279P Incidence, risk factors and management of medication-related osteonecrosis of the jaw in breast cancer patients treated with zoledronic acid or denosumab over a 5-year period in a UK tertiary institution
2024
·
O. Akala
, S. Bhagani
, et al.
·
ESMO Open
·
2
PDF
Decentralised Oncology Trials in the UK: Evidence, Regulation and Academic Clinical Trials Units’ Perspectives
2026
·
Oyeyemi Akala
, Harriet S Walter
, et al.
·
BMJ Oncology
·
1
Incidence and Management of Transtuzumab Emtansine- and Transtuzumab Deruxetecan-related Pneumonitis in Breast Cancer Patients within Leicester
2024
·
S. Bhagani
, O. Akala
·
Clinical Oncology
·
1
PDF
Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer
2026
·
Mohamed Sheeraz Mohamed Azhar
, Oghenevwede Okuma
, et al.
·
Clinical Oncology
Real-world Effectiveness and Safety of Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: a Single-centre Cohort With Exploratory Her2-low Subgroup Analysis
2025
·
Mohamed Sheeraz Mohamed Azhar
, Yetunde Owoseni
, et al.
·
The Breast
P34.04 Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre
2021
·
S. Dulloo
, O. Akala
, et al.
·
Journal of Thoracic Oncology
Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience
2021
·
Sean Dulloo
, Manar Almusarhed
, et al.
·
Lung Cancer
EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations – real world data
2021
·
Sean Dulloo
, Manar Almusarhed
, et al.
·
Lung Cancer
P113 Domestic violence – do we ask? will they tell?
2017
·
Nicola Dearing
, Oyeyemi Akala
, et al.
·
Sexually Transmitted Infections
PDF
Show more works
View as search
Works count:
11
Citation count:
33
H-index:
2
I10-index:
1
Year
Topic
Type